Transdermal administration of memantine

US10363228B2 · kind B2 · utility

Assignees

• LTS Lohmann Therapie-Systeme AG · DE
• Gruenenthal GmbH · DE

Inventors

• René Eifler · Koblenz, DE
• Michael Horstmann · Neuwied, DE
• Regine Kaufmann · Neuwied, DE
• Patrick Mohr · Mims, US
• Eric Galia · Jülich, DE
• Wolfgang PRANGE · Grafschaft, DE
• Stefan Buller · Baesweiler, DE
• Klaus Pusecker · Korschenbroich, DE
• Jan Stampfuss · Goldkronach, DE
• Susanne Stoelben · Cologne, DE

Key dates

• Filing date: Jun 17, 2011
• Grant date: Jul 30, 2019
• Expiry date: Sep 14, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.